« Return to News | CROs/Service Providers | Drug Sponsors

Danaher to acquire Iris International for $19.50 per share

Monday, September 17, 2012 02:52 PM

Danaher, a science and technology company, has agreed to acquire Iris International, a manufacturer of automated in vitro diagnostics systems and provider of personalized medicine solutions, for $19.50 per share in cash, representing an approximate 45% premium over the closing price of Iris's common stock on September 14, 2012.

"The board of directors voted unanimously to accept Danaher's proposal as it provides for an immediate compelling cash premium realization for our shareholders,” said César M. García, chairman, president and CEO of Iris International. “Further, Iris will benefit from being a part of a larger organization with significant resources to enable the acceleration of its diversified product pipeline strategy."

An affiliate of Danaher is expected to commence a tender offer for all of Iris' outstanding common stock within the next seven days, which will remain open for a minimum of 20 business days following its commencement. The tender offer is conditioned upon at least a majority of Iris' outstanding shares being tendered, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

The transaction is structured as a tender offer followed by a merger and is expected to be completed in the fourth quarter of 2012. Upon closing, Iris will become part of Danaher's Beckman Coulter Diagnostics business.

Citi is acting as financial advisor and Stubbs Alderton & Markiles is serving as legal counsel to Iris in connection with the transaction.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.